The 429 monoclonal antibody specifically binds to both the long (~110 kDa) transmembrane-spanning form and the truncated (~47 kDa) GPI-linked form of vascular cell adhesion molecule-1 (VCAM-1, CD106). CD106 is constitutively expressed on bone marrow stromal cells, myeloid cells, and splenic dendritic cells. Its expression on endothelial cells is upregulated by inflammatory cytokines and in certain pathologic conditions. CD106 expression has also been detected on apoptotic thymocytes, splenocytes, and lymphoid cell lines. VCAM-1 is a counter-receptor for VLA-4 (α4β1 integrin) and LPAM-1 (α4β7 integrin), and the 429 antibody partially blocks VCAM-1-mediated binding functions. Source of the immunogen was the mouse preadipose cell line PA6.
The antibody was conjugated to BD Horizon™ BB700, which is part of the BD Horizon Brilliant™ Blue family of dyes. It is a polymer-based tandem dye developed exclusively by BD Biosciences. With an excitation max of 485 nm and an emission max of 693 nm, BD Horizon BB700 can be excited by the 488 nm laser and detected in a standard PerCP-Cy™5.5 set (eg, 695/40-nm filter). This dye provides a much brighter alternative to PerCP-Cy5.5 with less cross laser excitation off the 405 nm and 355 nm lasers.